"Our project is innovative in its use of advanced epigenetic techniques combined with a novel preclinical model of PDAC survivorship," Dr. Arneson-Wissink said. "Together, these tools allow us to ...

MUNICH--(BUSINESS WIRE)--CatalYm today announced new findings from its ongoing Phase 1/2a study as well as preclinical research, highlighting the therapeutic potential of its lead drug candidate, ...

Until recently, the root cause of cachexia was identified as the inflammatory mediators produced either by the tumour itself ...

Cancer cachexia impacts almost 90% of people living with pancreatic cancer. Learn more about this condition in this Q&A with Nicolas Clifford, PanCAN’s manager of research and education communication.

Pfizer researchers say they are developing a drug that might counteract a condition that leads to the death of cancer patients within a year of its diagnosis. Photo by Stephanie Lecocq/EPA-EFE Sept.

Cachexia in older SCLC patients leads to inferior survival rates and increased treatment complications, such as dose reductions and incomplete chemotherapy courses. Patients with cachexia had ...

Cachexia, defined as a loss of body weight, fat, and muscle mass that occurs in patients with chronic diseases, including cancer, remains a notable clinical challenge. With limited viable treatment ...

Understanding the importance of using the right diagnostic criteria for cachexia is crucial, as it can significantly influence the health and survival of cancer patients. Maintaining good health and ...

Maintaining good health and well-being is crucial for how well patients respond to cancer treatments. Unfortunately, cachexia, or involuntary weight loss, is a major concern for many individuals with ...

Sept. 14 (UPI) --A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical tests, drugmaker Pfizer announced Saturday. The experimental ...